Healthcare Global Enterprises profit and loss

Latest FY26

Revenue: ₹2,545cr+14.5% on FY25
EBITDA: ₹466cr+20.3% on FY25
Net profit: ₹22.8cr−53.3% on FY25
EPS: ₹0.97−69.6% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	2,627	2,545	2,223	1,912	1,694	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	30.3	25.0	34.8	16.9	13.2
	2,658	2,570	2,258	1,929	1,708
	722	702	590	479	432
	−13.0	−9.4	−9.6	−4.0	−8.3
	385	379	353	308	275
	171	177	155	109	104
	257	244	211	174	163
	1,053	1,009	901	799	697
	2,575	2,500	2,201	1,866	1,663
	480	466	387	330	299
	224	222	176	155	135
Profit
	82.9	70.0	56.2	63.4	44.9
	−44.6	−44.6	0.0	3.9	0.0
	38.3	25.5	56.2	67.3	44.9
	19.6	19.8	28.7	34.3	15.4
	−12.8	−15.6	−20.5	−7.9	11.9
	6.8	4.1	8.1	26.4	27.3
	1.7	1.5	0.8	0.4	−0.0
	33.3	22.8	48.8	41.3	17.6
	31.6	21.3	48.1	40.9	17.6
	4.8	4.6	1.8	−0.5	−1.3
	38.1	27.3	50.6	40.9	16.3
	22.8	13.8	44.4	48.1	29.3
	10.5	9.0	4.4	−6.8	−11.7
Per share
	₹1.55	₹0.97	₹3.19	₹3.46	₹2.11
	₹1.55	₹0.96	₹3.14	₹3.43	₹2.10
Revenue detail — as filed
	—	1.5	0.8	0.4	−0.0
Other comprehensive income — detail
	4.8	4.6	1.8	—	—
	0.8	0.7	0.1	−0.7	−0.4
	0.1	0.0	0.0	—	—
	4.1	3.8	1.7	0.2	−0.9
	27.6	18.3	46.0	47.7	27.9
	10.4	9.0	4.6	−6.9	−11.6
Per share — as-filed variants
	₹1.55	₹0.97	₹3.19	₹3.46	₹2.11
	₹1.55	₹0.96	₹3.14	₹3.43	₹2.10
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,918	1,853	1,642	1,437	1,270
	73.0%	72.8%	73.9%	75.1%	75.0%
Adjusted (ex-exceptional items) — derived
	82.9	70.0	56.2	63.4	44.9
	−44.6	−44.6	0.0	3.9	0.0
	70.0	60.1	48.8	38.9	17.6
	₹3.26	₹2.56	₹3.19	₹3.26	₹2.11

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HCG₹591.45

Healthcare Global Enterprises Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAPOLLOHOSP FORTIS RAINBOW JLHL CORONA MARKSANS METROPOLIS PARKHOSPSMcap ₹8,511 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,694.4	1,912.1	2,222.9	2,545.4	2,627.4
Other Income	13.2	16.9	34.8	25.0	30.3
Total Income	1,707.6	1,929.1	2,257.7	2,570.4	2,657.6
Expenses
+ Purchases of Stock-in-Trade	432.4	479.4	590.2	701.7	722.2
+ Changes in Inventories	-8.3	-4.0	-9.6	-9.4	-13.0
+ Employee Benefit Expense	275.1	308.2	353.5	378.6	385.4
+ Finance Costs	103.5	108.7	154.6	176.6	171.0
+ Depreciation & Amortisation	163.5	174.4	211.3	244.2	256.7
+ Other Expenses	696.6	798.9	901.5	1,008.7	1,052.5
Total Expenses	1,662.7	1,865.6	2,201.5	2,500.4	2,574.7
EBITDA	298.7	329.6	387.3	465.8	480.3
EBIT	135.2	155.2	175.9	221.6	223.6
Profit
PBT before Exceptional Items	44.9	63.4	56.2	70.0	82.9
+ Exceptional Items	0.0	3.9	0.0	-44.6	-44.6
Pretax Income	44.9	67.3	56.2	25.5	38.3
+ Current Tax	15.4	34.3	28.7	19.8	19.6
+ Deferred Tax	11.9	-7.9	-20.5	-15.6	-12.8
Tax Expense	27.3	26.4	8.1	4.1	6.8
+ Share of Associates & JVs	-0.0	0.4	0.8	1.5	1.7
Net Income	17.6	41.3	48.8	22.8	33.3
+ Net Income — Continuing Ops	17.6	40.9	48.1	21.3	31.6
+ Other Comprehensive Income	-1.3	-0.5	1.8	4.6	4.8
Total Comprehensive Income	16.3	40.9	50.6	27.3	38.1
Net Income to Common	29.3	48.1	44.4	13.8	22.8
Minority Interest	-11.7	-6.8	4.4	9.0	10.5
Per Share
Basic EPS	2.11	3.46	3.19	0.97	1.55
Diluted EPS	2.10	3.43	3.14	0.96	1.55
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs	-0.0	0.4	0.8	1.5	—
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	1.8	4.6	4.8
+ Items NOT to be Reclassified to P&L	-0.4	-0.7	0.1	0.7	0.8
+ Tax on Items NOT to be Reclassified	—	—	0.0	0.0	0.1
+ Items to be Reclassified to P&L	-0.9	0.2	1.7	3.8	4.1
Comprehensive Income — Owners of Parent	27.9	47.7	46.0	18.3	27.6
Comprehensive Income — Non-controlling Interests	-11.6	-6.9	4.6	9.0	10.4
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.11	3.46	3.19	0.97	1.55
Diluted EPS — Continuing Operations	2.10	3.43	3.14	0.96	1.55
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,270.4	1,436.7	1,642.3	1,853.1	1,918.1
Gross Margin %	74.97	75.14	73.88	72.80	73.01
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	44.9	63.4	56.2	70.0	82.9
− Exceptional Items (reconciliation)	0.0	3.9	0.0	-44.6	-44.6
Net Income Adj (tax-effected)	17.6	38.9	48.8	60.1	70.0
EPS Adj	2.11	3.26	3.19	2.56	3.26
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	139.1	139.3	139.4	143.9	149.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.